相关实验视频
Updated: Jan 9, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.4K
进展的时间是复发或耐火性扩散大B细胞淋巴瘤生存的简单而强大的预后因素
Chieh-Lung Cheng1, Tai-Chung Huang2, Yu-Hsuan Tuan2
1Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 10002, Taiwan.
Therapeutic advances in medical oncology
|December 9, 2025
概括
在R-CHOP后进展的时间是扩散性大B细胞淋巴瘤患者复发或耐药疾病的关键预测因素. 进展时间较短表明预后较差,需要新的治疗方法.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床研究 临床研究
背景情况:
- 在R-CHOP治疗后复发或耐药 (R/R) 扩散性大B细胞淋巴瘤 (DLBCL) 构成了重大的临床挑战.
- 现实世界的数据对于了解R/R DLBCL管理和未满足需求至关重要.
研究的目的:
- 在R/R DLBCL患者中确定总生存 (OS) 和无进展生存 (PFS) 的预后因素.
- 在现实环境中验证时间到进展 (TTP) 的预后意义.
主要方法:
- 在接受R-CHOP治疗的R/R DLBCL患者进行了回顾性观察性研究.
- 外部验证使用基于国家人口的队列.
- 考克斯比例危险回归分析,以确定OS和PFS的独立预测因素.
主要成果:
- 在R-CHOP之后的进展时间 (TTP) 被确定为OS和PFS的独立预后因素.
- 患有TTP<12个月的患者的OS率明显较低 (35.4%),二线治疗结果较差.
- 在723名R/R DLBCL患者的外部队列中验证了TTP的预后意义.
结论:
- 进展时间 (TTP) 是R/R DLBCL的强大且易于应用的预后预测指标.
- 患有TTP<12个月的患者在目前的治疗方法下预后不好,这表明需要新的治疗策略.
相关概念视频
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630

